Professor of Biology Karen Hubbard, Division of Science
Researchers at The City College of New York have linked chemotherapy treatment to lasting cognitive changes in rats – potentially shedding light, for the first time, on cognitive problems some cancer survivors experience long after treatment ends. Entitled “Chemotherapy treatment alters DNA methylation patterns in the prefrontal cortex of female rat brain,” the study appears in the journal Nature: Scientific Reports.
“Our study explored how chemotherapy affects the brain at the molecular level using an animal model,” said Karen Hubbard, professor of biology in CCNY’s Division of Science, who co-led the study. “We found that chemotherapy doesn’t just target cancer cells — it also disrupts how genes are regulated in the brain, specifically in the prefrontal cortex, the area responsible for decision-making and executive function.”
For the first time, the team showed that a commonly used chemotherapy combination — doxorubicin and cyclophosphamide — significantly increases the expression of DNMT3a, a gene involved in adding methylation marks to DNA. This change was linked to altered DNA methylation patterns in key brain regions, which may help explain why many cancer patients experience long-term cognitive issues after treatment, often referred to as “chemo brain.”
The study, Hubbard added, offers a biological explanation for these cognitive problems that many cancer survivors, especially breast cancer patients, report long after treatment ends.
This may help to identify patients who are most vulnerable to cognitive side effects, and guide the development of targeted epigenetic therapies, such as DNMT or HDAC inhibitors, to prevent or even reverse chemotherapy-induced cognitive decline.
The research continues at CCNY with focus on investigating the role of RNA-binding proteins, which are known to be involved in brain aging, in both the prefrontal cortex and hippocampus of the team’s chemotherapy-treated animal model. “This work aims to further uncover how chemotherapy disrupts molecular pathways linked to cognitive decline.”
Other members of Hubbard’s team include (all CCNY unless indicated): Shami Chakrabarti, Chanchal Wagh, Ciara Bagnall-Moreau (CCNY/Institute of Molecular Medicine, The Feinstein Institute of Medical Research), Fathema Uddin, Joshua Reiser, Kaliris Salas-Ramirez (CUNY School of Medicine), and Tim Ahles (Memorial Sloan Kettering Cancer Center).
About The City College of New York
Since 1847, The City College of New York has provided a high-quality and affordable education to generations of New Yorkers in a wide variety of disciplines. CCNY embraces its position at the forefront of social change. It is ranked #1 by the Harvard-based Opportunity Insights out of 369 selective public colleges in the United States on the overall mobility index. This measure reflects both access and outcomes, representing the likelihood that a student at CCNY can move up two or more income quintiles. Education research organization Degree Choices ranks CCNY #1 nationally among universities for economic return on investment. In addition, the Center for World University Rankings places CCNY in the top 1.8% of universities worldwide in terms of academic excellence. Labor analytics firm Lightcast puts at $3.2 billion CCNY’s annual economic impact on the regional economy (5 boroughs and 5 adjacent counties) and quantifies the “for dollar” return on investment to students, taxpayers, and society. At City College, more than 16,500 students pursue undergraduate and graduate degrees in eight schools and divisions, driven by significant funded research, creativity, and scholarship. In 2023, CCNY launched its most expansive fundraising campaign ever. The campaign, titled “Doing Remarkable Things Together,” seeks to bring the College’s Foundation to more than $1 billion in total assets in support of the College's mission. CCNY is as diverse, dynamic, and visionary as New York City itself. View CCNY Media Kit.
Jay Mwamba
212-650-7580
jmwamba@ccny.cuny.edu